Literature DB >> 26401262

Pulmonary hypertension complicating multiple myeloma.

Udhay Krishnan1, Tomer M Mark2, Ruben Niesvizky2, Irina Sobol1.   

Abstract

Pulmonary hypertension (PH) is an infrequently reported complication of multiple myeloma (MM). PH has been more commonly associated with amyloidosis, myeloproliferative diseases, and the POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome. PH in MM is typically mild to moderate and may be secondary to a variety of conditions, which include left ventricular dysfunction, high-output cardiac failure, chronic kidney disease, treatment-related toxicities, and precapillary involvement. We describe 3 patients with MM and severe PH. Each patient underwent right heart catheterization. All patients demonstrated elevated pulmonary pressures, transpulmonary gradients, and pulmonary vascular resistance. Each patient was ultimately treated with pulmonary vasodilator therapy with improvement in cardiopulmonary symptoms. Additional studies are needed to define the prevalence, prognosis, and pathogenesis of PH in this complex population and to help clarify who may benefit from targeted PH therapy.

Entities:  

Keywords:  amyloidosis; multiple myeloma; pulmonary hypertension; pulmonary vasculature

Year:  2015        PMID: 26401262      PMCID: PMC4556512          DOI: 10.1086/682430

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  43 in total

Review 1.  Soluble immune mediators in POEMS syndrome with pulmonary hypertension: case report and review of the literature.

Authors:  L Feinberg; D Temple; E de Marchena; R Patarca; A Mitrani
Journal:  Crit Rev Oncog       Date:  1999

2.  Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.

Authors:  Tallal Hussein Younis; Arif Alam; Pamela Paplham; Edward Spangenthal; Philip McCarthy
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

3.  Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.

Authors:  E Antonioli; C Nozzoli; G Gianfaldoni; F Mannelli; S Rossi; S Betti; P Bernardeschi; G Fiorentini; A Bosi
Journal:  Ann Oncol       Date:  2005-07-12       Impact factor: 32.976

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

5.  Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines.

Authors:  P Lesprit; B Godeau; F J Authier; M Soubrier; M Zuber; C Larroche; J P Viard; B Wechsler; R Gherardi
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

6.  POEMS syndrome: definitions and long-term outcome.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; S Vincent Rajkumar; Terry M Therneau; Dirk R Larson; Philip R Greipp; Thomas E Witzig; Rita Basu; Guillermo A Suarez; Rafael Fonseca; John A Lust; Morie A Gertz
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

7.  Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications.

Authors:  Mona Amin; Ashraf Fawzy; Magdy Abdel Hamid; Abdou Elhendy
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

8.  Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma.

Authors:  W McBride; J D Jackman; P A Grayburn
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

Review 9.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

10.  Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study.

Authors:  C Lafaras; E Mandala; E Verrou; D Platogiannis; N Barbetakis; T Bischiniotis; K Zervas
Journal:  Ann Oncol       Date:  2008-05-13       Impact factor: 32.976

View more
  2 in total

1.  Gamma heavy chain disease complicated by pulmonary hypertension, which was successfully treated with lenalidomide.

Authors:  Sho Shibata; Akiko Fukunaga
Journal:  BMJ Case Rep       Date:  2020-11-30

2.  Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia.

Authors:  Indranee Rajapreyar; Joanna Joly; Jose Tallaj; Salpy V Pamboukian; Ayman Haj Assad; Carrie Lenneman; Silvio Litovsky; Arka Chatterjee; Charles Hoopes; Andrew Lenneman
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2020-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.